Home/Filings/4/0000895345-24-000019
4//SEC Filing

LEWIS JOSEPH 4

Accession 0000895345-24-000019

CIK 0001576263other

Filed

Jan 24, 7:00 PM ET

Accepted

Jan 25, 4:32 PM ET

Size

32.4 KB

Accession

0000895345-24-000019

Insider Transaction Report

Form 4
Period: 2024-01-23
Transactions
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
LEWIS JOSEPH
10% Owner
Transactions
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
Transactions
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
Transactions
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
Transactions
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
Transactions
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
Transactions
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
Transactions
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
Braslyn Ltd.
10% Owner
Transactions
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-233,578,0360 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-01-06Common Stock (3,578,036 underlying)
  • Disposition to Issuer

    Common Stock

    2024-01-23287,8660 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-23203,7540 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-2330,5180 total(indirect: See Footnote)
  • Disposition to Issuer

    Common Stock

    2024-01-233,201,4400 total
  • Disposition to Issuer

    Common Stock

    2024-01-233,135,9660 total(indirect: See Footnote)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-23332,8090 total
    Exercise: $0.00From: 2017-11-20Common Stock (332,809 underlying)
  • Disposition to Issuer

    Warrant (right to purchase)

    2024-01-231,413,4750 total(indirect: See Footnote)
    Exercise: $0.00From: 2017-11-20Common Stock (1,413,475 underlying)
Footnotes (8)
  • [F1]On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
  • [F2]These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
  • [F3]These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
  • [F4]These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.
  • [F5]These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
  • [F6]These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.
  • [F7]By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.
  • [F8]These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

Documents

1 file

Issuer

Mirati Therapeutics, Inc.

CIK 0001576263

Entity typeother

Related Parties

1
  • filerCIK 0001015747

Filing Metadata

Form type
4
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 4:32 PM ET
Size
32.4 KB